Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer

E-ISSN： 1873-4286|20|24|3933-3943

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.24, 2014-05, pp. : 3933-3943

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations

By Park In Kim Jin Jung Jae Han Ji-Youn

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 791-799

Springer Publishing Company

Access to resources Recommend Favorite

EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer

By de Mello Ramon Andrade Madureira Pedro Carvalho Liliana S Araújo António O’Brien Mary Popat Sanjay

Pharmacogenomics, Vol. 14, Iss. 14, 2013-11 ,pp. : 1765-1777

Future Medicine

Access to resources Recommend Favorite

Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells

Current Pharmaceutical Design, Vol. 19, Iss. 5, 2013-02 ,pp. : 927-939

Bentham Science Publishers

Access to resources Recommend Favorite

Non–Small Cell Lung Cancer

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 3, 2008-03 ,pp. : 228-228

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Gefitinib is an effective treatment for patients with non-small-cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor

Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite